TY  - JOUR
PY  - 2021//
TI  - Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials
JO  - Journal of affective disorders
A1  - Chen, Mu-Hong
A1  - Wu, Hui-Ju
A1  - Li, Cheng-Ta
A1  - Lin, Wei-Chen
A1  - Bai, Ya-Mei
A1  - Tsai, Shih-Jen
A1  - Hong, Chen-Jee
A1  - Tu, Pei-Chi
A1  - Cheng, Chih-Ming
A1  - Su, Tung-Ping
SP  - 865
EP  - 871
VL  - 281
IS  - 
N2  - BACKGROUND: Evidence suggests that clinical markers, such as comorbid anxiety, body weight, and others can assist in predicting response to low-dose ketamine infusion in treatment resistant depression patients. However, whether a composite of clinical markers may improve the predicted probability of response is uncertain.  METHODS: The current study investigated the results of our previous randomized placebo-controlled and open-label trials in which 73 patients with treatment-resistant depression (TRD) received a single ketamine infusion of 0.5 mg/kg. Clinical characteristics at baseline, including depression severity, duration of the current episode, obesity, comorbidity of anxiety disorder, and current suicide risk, were assessed as potential predictors in a classification and regression tree model for treatment response to ketamine infusion.  RESULTS: The predicted probability of a composite of age at disease onset, depression severity, duration of current episode, and obesity/overweight was significantly greater (area under curve = .736, p = .001) than that of any one marker (all p > .05). The most powerful predictors of treatment response to ketamine infusion were younger age at disease onset and obesity/overweight. The strongest predictors of treatment nonresponse were longer duration of the current episode and greater depression severity at baseline.  DISCUSSION: Depression severity, duration of the current episode, obesity, and age at disease onset may predict treatment response versus nonresponse to low-dose ketamine infusion. However, whether our predicted probability for a single infusion may be applied to repeated infusions would require further investigation.  CLINICAL TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN000023581 and UMIN000016985).<p /> <p>Language: en</p>
LA  - en
SN  - 0165-0327
UR  - http://dx.doi.org/10.1016/j.jad.2020.11.045
ID  - ref1
ER  -